TLX

Q1 2024 Revenue and Business Update

Retrieved on: 
수요일, 4월 17, 2024
FDA, Drug discovery, Fast Track, Physics, TLX, NDA, Food, ASX, Research, Biologics license application, IND, Prostate cancer, Science, Chemistry, Acquisition, BLA, Breakthrough therapy, Growth, Radiochemistry, Medical imaging

MELBOURNE, Australia, April 17, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter ended 31 March 2024 (Q1 2024).

Key Points: 
  • MELBOURNE, Australia, April 17, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today provides an update on its revenue and operational performance for the quarter ended 31 March 2024 (Q1 2024).
  • U.S. revenue grew by 18% to US$111.8M (US$95.1M in Q4 2023), compared to 11% growth between Q3 2023 and Q4 2023.
  • Dr Christian Behrenbruch, Managing Director and Group CEO of Telix, commented, “The continued, consistent growth of our precision diagnostics business is further evidence of an effective market growth strategy for our prostate cancer franchise.
  • Telix reaffirms guidance provided on 22 February 2024 for full year revenue expected to be in the range of US$445M to $465M (AU$675M to $705M at current exchange rates), representing an approximate 35-40% increase versus 2023.

QSAM ANNOUNCES REVERSE STOCK SPLIT RATIO AHEAD OF MERGER

Retrieved on: 
화요일, 4월 16, 2024
Agreement, TLX, OTCQB, ASX, Plan, Reverse stock split, Telix, Common stock, Information, QSAM, Security (finance)

Austin, TX, April 16, 2024 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc. (OTCQB: QSAM) (“QSAM” or the “Company”) previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM’s common stock, par value $0.0001 per share (“Common Stock”), at a ratio in the range of 1:1000 to 1:2000, prior to the closing of the merger between the Company and Telix Pharmaceuticals Limited (ASX: TLX) (“Telix”) pursuant to which Telix will acquire QSAM (the “Merger”).

Key Points: 
  • Austin, TX, April 16, 2024 (GLOBE NEWSWIRE) -- QSAM Biosciences, Inc. (OTCQB: QSAM) (“QSAM” or the “Company”) previously announced that it will effectuate a reverse stock split of the issued and outstanding shares of QSAM’s common stock, par value $0.0001 per share (“Common Stock”), at a ratio in the range of 1:1000 to 1:2000, prior to the closing of the merger between the Company and Telix Pharmaceuticals Limited (ASX: TLX) (“Telix”) pursuant to which Telix will acquire QSAM (the “Merger”).
  • On April 15, 2024, the Board of Directors of QSAM unanimously approved that the reverse stock split ratio be 1-for-2,000 such that once the reverse stock split goes into effect, every holder of Common Stock of the Company shall receive one share of Common Stock for every 2,000 shares of Common Stock held (the “Reverse Stock Split”).
  • On February 7, 2024, a majority of the voting shareholders of QSAM approved the reverse stock split and granted the Board the discretion to adopt the ratio prior to the closing of the Merger, which ratio the Board has adopted and is announcing today.
  • QSAM shareholders are encouraged to review the Information Statement for further information about the Merger and the Reverse Stock Split, which can be found on the SEC Edgar database: QSAM Definitive Information Statement .

TLX101-CDx (Pixclara™) Granted FDA Fast Track Designation

Retrieved on: 
월요일, 4월 15, 2024
FDA, University, Fast Track, Pharmacy, Food and Drug Administration, TLX, NDA, Food, Radiology, MD, ASX, PET, Partnership, Research, Glioma, UCSF, Patient, FET, Radiopharmaceutical, 18F-FET, Diagnosis

MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has granted Fast Track designation1 for the Company’s investigational glioma imaging product, TLX101-CDx (Pixclara™2, 18F-floretyrosine or 18F-FET).

Key Points: 
  • MELBOURNE, Australia, April 16, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces that the United States (U.S.) Food and Drug Administration (FDA) has granted Fast Track designation1 for the Company’s investigational glioma imaging product, TLX101-CDx (Pixclara™2, 18F-floretyrosine or 18F-FET).
  • The granted Fast Track designation is for the characterisation of progressive or recurrent glioma using positron emission tomography (PET).
  • Concurrently, Telix is in the final stages of preparing its U.S. New Drug Application (NDA) for TLX101-CDx in this initial indication, in both adult and paediatric patients.
  • This designation enables expedited review and closer consultation with the FDA during the review process.

World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain

Retrieved on: 
화요일, 3월 26, 2024
Diagnosis, Biopsy, Sentinel lymph node, Radiation, Prostate cancer, Patient, ASX, SLN, Prostate, Bladder cancer, Hospital, TLX, Lymph node, Health technology, Medtech, AA, Medical imaging

SENSEI® is smaller than an AA battery and designed specifically for robotic-assisted and minimally invasive surgery.

Key Points: 
  • SENSEI® is smaller than an AA battery and designed specifically for robotic-assisted and minimally invasive surgery.
  • The miniature size and proprietary features make the technology ideal for tight surgical spaces such as around the bladder.
  • Radio-guided surgery has historically been limited by the fact that gamma probes are generally only suitable for open surgery.
  • Nynke van den Berg, General Manager Medical Technologies (MedTech) at Telix added, “A first bladder cancer procedure with the SENSEI® drop-in gamma probe is a significant milestone for Telix and the Lightpoint team.

QDOSE® Platform Partnership for Personalized Dosimetry in Radiopharmaceutical Therapy

Retrieved on: 
월요일, 3월 18, 2024
Radiation, CE, Artificial intelligence, ASX, European, TLX, FDA, Medical imaging

QDOSE® is a validated, versatile software platform that enables reliable estimation of patient-specific dosimetry for both therapeutic and diagnostic radiopharmaceuticals.

Key Points: 
  • QDOSE® is a validated, versatile software platform that enables reliable estimation of patient-specific dosimetry for both therapeutic and diagnostic radiopharmaceuticals.
  • Telix intends to integrate the QDOSE® platform into its therapeutic radiopharmaceutical programs and clinical collaborations to enable the development of personalized treatment regimens.
  • Personalized radiopharmaceutical therapy administration based on individual patient dosimetry has the potential to improve clinical outcomes by optimizing treatment response while reducing effects on normal healthy organs and optimizing the use of isotope supply chains.
  • Rapid, reliable and personalized dosimetry is becoming an increasingly important future direction of cancer care and regulatory authorities now expect to see dosimetry analysis.

World First Use of Lightpoint's SENSEI® Drop-In Gamma Probe in Bladder Cancer Surgery Performed in Spain

Retrieved on: 
화요일, 3월 26, 2024
Diagnosis, Biopsy, Sentinel lymph node, Radiation, Prostate cancer, Patient, ASX, SLN, Prostate, Bladder cancer, Hospital, TLX, Lymph node, Health technology, Medtech, AA, Medical imaging

SENSEI® is smaller than an AA battery and designed specifically for robotic-assisted and minimally invasive surgery.

Key Points: 
  • SENSEI® is smaller than an AA battery and designed specifically for robotic-assisted and minimally invasive surgery.
  • The miniature size and proprietary features make the technology ideal for tight surgical spaces such as around the bladder.
  • Radio-guided surgery has historically been limited by the fact that gamma probes are generally only suitable for open surgery.
  • Nynke van den Berg, General Manager Medical Technologies (MedTech) at Telix added, "A first bladder cancer procedure with the SENSEI® drop-in gamma probe is a significant milestone for Telix and the Lightpoint team.

QDOSE® Platform Partnership for Personalised Dosimetry in Radiopharmaceutical Therapy

Retrieved on: 
월요일, 3월 18, 2024
Radiation, CE, ASX, European, TLX, FDA, Nuclear medicine, Medical imaging

QDOSE® is a validated, versatile software platform that enables reliable estimation of patient-specific dosimetry for both therapeutic and diagnostic radiopharmaceuticals.

Key Points: 
  • QDOSE® is a validated, versatile software platform that enables reliable estimation of patient-specific dosimetry for both therapeutic and diagnostic radiopharmaceuticals.
  • Telix intends to integrate the QDOSE® platform into its therapeutic radiopharmaceutical programs and clinical collaborations to enable the development of personalised treatment regimens.
  • Personalised radiopharmaceutical therapy administration based on individual patient dosimetry has the potential to improve clinical outcomes by optimising treatment response while reducing effects on normal healthy organs and optimising the use of isotope supply chains.
  • Rapid, reliable and personalised dosimetry is becoming an increasingly important future direction of cancer care and regulatory authorities now expect to see dosimetry analysis.

Appointment of Dr Darren Patti to Group Chief Operating Officer

Retrieved on: 
월요일, 3월 11, 2024
Pharming, ASX, University, Medicine, TLX, Operation

MELBOURNE, Australia, March 11, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce the appointment of Dr. Darren Patti as Group Chief Operating Officer (COO), effective 11 March 2024.

Key Points: 
  • MELBOURNE, Australia, March 11, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce the appointment of Dr. Darren Patti as Group Chief Operating Officer (COO), effective 11 March 2024.
  • Dr. Patti joined Telix in March 2021 to lead the Company's United States (U.S.) operations.
  • Prior to joining Telix, Darren held a variety of roles at Sofie Biosciences over a period of 15 years, most recently as Vice President of Operations leading the operationalisation of the Sofie-Lantheus PSMA-PET imaging program.
  • Dr. Christian Behrenbruch, Managing Director and Group CEO commented, "Darren has been an exemplary leader in our Americas region and fundamental to the success of our commercial operations and vertical integration strategy.

Appointment of Dr Darren Patti to Group Chief Operating Officer

Retrieved on: 
월요일, 3월 11, 2024
TLX, ASX, University, Pharming, Operation

MELBOURNE, Australia, March 12, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce the appointment of Dr. Darren Patti as Group Chief Operating Officer (COO), effective 11 March 2024.

Key Points: 
  • MELBOURNE, Australia, March 12, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) is pleased to announce the appointment of Dr. Darren Patti as Group Chief Operating Officer (COO), effective 11 March 2024.
  • Dr. Patti joined Telix in March 2021 to lead the Company’s United States (U.S.) operations.
  • Prior to joining Telix, Darren held a variety of roles at Sofie Biosciences over a period of 15 years, most recently as Vice President of Operations leading the operationalisation of the Sofie-Lantheus PSMA-PET imaging program.
  • Dr. Christian Behrenbruch, Managing Director and Group CEO commented, “Darren has been an exemplary leader in our Americas region and fundamental to the success of our commercial operations and vertical integration strategy.

Telix to Acquire ARTMS, Inc. and its Advanced Isotope Production Platform

Retrieved on: 
월요일, 3월 4, 2024
Acquisition, Pharmacy, TMS, TRIUMF, Actinium-225, Chemistry, Isotope, Sale, TLX, Physics, ASX, Clinical trial, Science, Ultra, Research, Partnership, Medical imaging

MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire radioisotope production technology firm ARTMS Inc. (ARTMS), its advanced cyclotron-based isotope production platform, manufacturing plant and stockpile of ultra-pure rare metals required for consumable target production.

Key Points: 
  • MELBOURNE, Australia, March 05, 2024 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire radioisotope production technology firm ARTMS Inc. (ARTMS), its advanced cyclotron-based isotope production platform, manufacturing plant and stockpile of ultra-pure rare metals required for consumable target production.
  • Telix is currently validating multiple production locations of large-scale 89Zr production in the United States (U.S.) using the QIS system and select manufacturing and pharmacy partners.
  • ARTMS and Telix have been collaborating since 20202 to evaluate the potential of higher curie-scale (Ci) production of Illuccix®.
  • As part of the acquisition, Telix will also acquire the benefit of ARTMS’s production facility and clean rooms, located in Burnaby, BC (Canada).